Hints and tips:
Related Special Reports
...Despite Novo Nordisk and Eli Lilly’s lead, Steensberg believed there was space for others to develop weight-loss products....
...Eli Lilly has made cuts in Europe and reduced the number of clinical trials there, he added. But some campaigners for access to medicines welcomed the proposals....
...Eli Lilly’s weight-loss drug tirzepatide significantly reduced sleep apnoea problems in a late-stage clinical trial, the pharmaceutical group said on Wednesday, adding to evidence that could encourage more...
...The push into prescriptions and drug delivery is unusual for a pharmaceutical manufacturer, pitting Eli Lilly against US pharmacy chains such as CVS and Walgreens. Read more here...
...“We’re pleased to work with Lilly to reimagine a pharmacy experience that can support better care outcomes.”...
...But that is what Eli Lilly did this week....
...Developed respectively by Novo Nordisk and Eli Lilly, they are now being prescribed to millions of people....
...Lilly’s 2024 revenues are projected to total between $40.4bn and $41.6bn compared with $34.1bn in 2023....
...BSP previously produced Covid antibody treatment bamlanivimab for Eli Lilly....
...Eli Lilly’s share price fell as much as 2.4 per cent in early US trading before later recovering its losses....
...This will result in the FDA’s decision being delayed beyond the first quarter, Lilly added....
...Lilly’s shares were up 1 per cent in New York on Wednesday....
...Patients on the donanemab study had more advanced Alzheimer’s than patients on similar studies, Eli Lilly said....
...For now, the market is dominated by Lilly and Novo Nordisk, the Danish maker of Ozempic and Wegovy. But Lilly may yet have an edge....
...Sales of Mounjaro, Lilly’s drug for diabetes that is also used off-label for weight loss, were $1.4bn....
...The retail giant struck a deal earlier this month to dispense medication on behalf of Zepbound maker Eli Lilly’s direct-to-consumer service LillyDirect....
...This will enable Lilly to begin supply to the UK within weeks,” said Laura Steele, head of UK and northern Europe at Lilly....
...At the highest dose, patients had lost nearly 50lbs on average, Lilly said....
...“The obesity field is going to be dominated by those two guys [Novo Nordisk and Eli Lilly] and who wants to go up against them?” he said. “It would be super hard.”...
...Shares in Point, which closed at $6.67 on Monday, surged 83 per cent in pre-market trading to $12.25, just shy of the $12.50 offered by Lilly....
...On Monday, Lilly stock fell 2.4 per cent to $525.66. Shares in Point rose 85 per cent to $12.37....
...Eli Lilly’s $12.50 a share cash offer for Point represents a 50 per cent premium to the stock’s undisturbed three month average....
...On Sunday, it announced Lilly would pay $45mn upfront, with another $1.7bn to be paid when the project reached performance milestones, such as drugs reaching trials or approval....
...Both Leqembi and Eli Lilly’s new drug donanemab target amyloid, a toxic protein that builds up in the brain, usually before significant levels of tau develop....
International Edition